BIO:ON Insight #8 · Jul 12, 2026
The drug works. Now comes the fight over insurance, channels and trust
Lilly's oral obesity pill Foundayo starts slowly because of insurance coverage gaps, GSK and Hansoh's B7-H3 ADC extends survival in small-cell lung cancer, and AI startup Xaira goes looking for Big Pharma partners. Does a good drug always reach patients?
What I learned this week
What stayed with me this week was the feeling that the science has answered, but the world isn't ready yet. When you first get into biotech, it's easy to think passing Phase 3 is the finish line. But if you look at a drug's journey from lab to patient, clinical data is roughly the halfway point. The people who understand the other half — the language of insurance, channels and partnerships — are the ones who'll create real value in this industry. See you next issue. 🙏
Yaehyun Lee · Quoted from the Editor's Insight I wrote for this issue.
Stories in this issue
- Market Trends
Lilly's oral obesity pill Foundayo starts slowly amid PBM coverage gaps
Eli LillyFoundayo
- Clinical Trials
GSK × Hansoh ADC meets its survival endpoint in small cell lung cancer Phase 3
GSKHansohrisvutatug rezetecan
- Pipeline Analysis
Xaira Therapeutics explores Big Pharma co-development deals
Xaira Therapeutics
AI summary
- 1Lilly's oral obesity drug Foundayo had a slow first month, held back by insurance coverage barriers.
- 2GSK and Hansoh's B7-H3 ADC extended survival in small-cell lung cancer Phase 3 — a first for the target.
- 3Multi-billion-dollar AI drug startup Xaira came out of stealth looking for big pharma partners.
Relevant rolesMarket accessBDSales & marketing
Summary and tags generated by AI from the issue text.
References
- 1.Lilly's oral obesity pill Foundayo off to a slow start amid PBM coverage gaps (opens in a new tab)
Fierce Pharma, Jul 10, 2026
- 2.GSK × Hansoh ADC risvutatug rezetecan meets survival endpoint in SCLC Phase 3 (opens in a new tab)
Fierce Biotech, Jul 10, 2026
- 3.
Related insights
Other issues covering the same companies, drugs or topics